Literature DB >> 20383809

Neuroprotective effect of erythropoietin in amyotrophic lateral sclerosis (ALS) model in vitro. Ultrastructural study.

Ewa Nagańska1, Anna Taraszewska, Ewa Matyja, Paweł Grieb, Janina Rafałowska.   

Abstract

Erythropoietin (EPO) is a chemokine hormone that is widely distributed throughout the body including nervous system. For last years its role as cytokine involved in many physiological processes out of the bone marrow has been suggested. Moreover, it plays a very important role in CNS as potential neuroprotective agent. There is much evidence that EPO protects neuronal cells in vitro and in vivo models of brain injury, independently of its erythropoietic action. The aim of this study was to determine the potential neuroprotective effects of erythropoietin on the glutamate-mediated injury of motor neurons (MNs) in vitro. The study was performed on organotypic cultures of the rat lumbar spinal cord subjected to glutamate uptake blocker, DL-threo-beta-hydroxyaspartate (THA) and pretreated with EPO. Ultrastructural study evidenced that the spinal cord cultures pretreated with EPO exhibited less severe neuronal injury. The cultures exposed to EPO + THA showed inhibition of early MNs degeneration, including various mode of degenerative changes caused by THA, whereas in the later period the typical postsynaptic necrotic changes of neuronal cells occurred. However, the ultrastructural characteristics of apoptotic MNs changes were not observed during the whole period of observation. The results of this study indicate that, in the model of chronic glutamate excitotoxicity, EPO exhibits the neuroprotective ability mainly through prevention of apoptotic neuronal changes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20383809

Source DB:  PubMed          Journal:  Folia Neuropathol        ISSN: 1509-572X            Impact factor:   2.038


  12 in total

1.  Cervical spinal erythropoietin induces phrenic motor facilitation via extracellular signal-regulated protein kinase and Akt signaling.

Authors:  Erica A Dale; Irawan Satriotomo; Gordon S Mitchell
Journal:  J Neurosci       Date:  2012-04-25       Impact factor: 6.167

Review 2.  Unexpected benefits of intermittent hypoxia: enhanced respiratory and nonrespiratory motor function.

Authors:  E A Dale; F Ben Mabrouk; G S Mitchell
Journal:  Physiology (Bethesda)       Date:  2014-01

3.  Physiological characterization of human muscle acetylcholine receptors from ALS patients.

Authors:  Eleonora Palma; Maurizio Inghilleri; Luca Conti; Cristina Deflorio; Vittorio Frasca; Alessia Manteca; Floriana Pichiorri; Cristina Roseti; Gregorio Torchia; Cristina Limatola; Francesca Grassi; Ricardo Miledi
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-29       Impact factor: 11.205

4.  Regulation of nuclear TDP-43 by NR2A-containing NMDA receptors and PTEN.

Authors:  Mei Zheng; Mingxia Liao; Tianyuan Cui; Honglin Tian; Dong-Sheng Fan; Qi Wan
Journal:  J Cell Sci       Date:  2012-03-15       Impact factor: 5.285

5.  rhEPO Upregulates the PPARγ Pathway in Long-term Cultured Primary Nerve Cells via PI3K/Akt to Delay Cell Senescence.

Authors:  Huqing Wang; Ming Chen; Tao Zhang; Zhen Gao; Yu Gong; Xiaorui Yu; Haiqin Wu
Journal:  J Mol Neurosci       Date:  2022-05-03       Impact factor: 2.866

Review 6.  Therapeutic neuroprotective agents for amyotrophic lateral sclerosis.

Authors:  Rachna S Pandya; Haining Zhu; Wei Li; Robert Bowser; Robert M Friedlander; Xin Wang
Journal:  Cell Mol Life Sci       Date:  2013-07-18       Impact factor: 9.261

7.  Erythropoietin promotes peripheral nerve regeneration in rats by upregulating expression of insulin-like growth factor-1.

Authors:  Wei Wang; Dongsheng Li; Qing Li; Lei Wang; Guang Bai; Tao Yang; Qiang Li; Zhitu Zhu; Hongzhi Sun
Journal:  Arch Med Sci       Date:  2015-04-23       Impact factor: 3.318

8.  Erythropoietin protects cardiomyocytes from cell death during hypoxia/reperfusion injury through activation of survival signaling pathways.

Authors:  Asiya A Parvin; Raj A Pranap; U Shalini; Ajay Devendran; John E Baker; Anuradha Dhanasekaran
Journal:  PLoS One       Date:  2014-09-19       Impact factor: 3.240

Review 9.  Current Therapy of Drugs in Amyotrophic Lateral Sclerosis.

Authors:  Haiyan Lu; Wei Dong Le; Ya-Ying Xie; Xiao-Ping Wang
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

Review 10.  Erythropoietin: new directions for the nervous system.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Yan Chen Shang; Shaohui Wang
Journal:  Int J Mol Sci       Date:  2012-09-06       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.